Article Sidebar
Main Article Content
Abstract
Leukemia is the expansion of leukocyte cells in the bone marrow, which results in an increase in the number of leukocyte cells in the blood circulation and abnormal cell proliferation in the lymphatic tissue. The diagnosis of leukemia is established based on anamnesis, physical examination, and laboratory and confirmed by supporting examinations such as bone marrow aspiration to immunophenotyping. This literature review aimed to describe the role of immunophenotyping in the diagnosis of acute leukemia. The working process of immunophenotyping consists of a group of cells stained with a fluorochrome-conjugated antibody as a dye that is targeted to antigens on the cell surface. Most of these antigens are assigned a cluster of differentiation (CD) numbers. In conclusion, immunophenotyping analysis using multiparameter flow cytometry is an essential tool in detecting leukemia. Immunophenotyping examination is very useful for determining the diagnosis of leukemia. Targeted therapy is one of the modalities of leukemia therapy that is selective for certain cells that can be given based on the results of immunophenotyping.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
